Telesis Bio Pre-Announces Preliminary Fourth Quarter Financial Results

Provided By Globe Newswire

Last update: Jan 9, 2023

-- Record revenue of $9M in 4QFY22; Increase of 191% over 4QFY21

-- BioXp^® Revenue increased by 131% to $3M, in 4QFY22 over 4QFY21

-- Successful achievement of first technical milestone with Pfizer leveraging Telesis Bio’s SOLA platform for enzymatic DNA synthesis technology